IndustryCompany release

Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stage

🇺🇸 Silence Therapeutics plc (SLN) · Thu 12 Nov 2026

The RNAi company reported a $12.4M third-quarter loss and $247.7M in cash, alongside positive Phase 2 divesiran data in polycythemia vera and a pending acquisition by Merck KGaA.

Silence Therapeutics reported its third-quarter 2026 results on 12 November 2026, showing a net loss of $12.4M. According to the company's summary, the narrower loss reflected lower research and development spending.

The company ended the period with cash of $247.7M. That figure includes $201.3M raised in a public offering in August.

On the clinical side, Silence highlighted positive topline data from the Phase 2 SANRECO study of divesiran in polycythemia vera. The company also said it has secured an oral presentation slot at the 2026 ASH meeting. The summary available does not give detailed efficacy or safety figures from the trial.

The update also covers the definitive agreement under which Merck KGaA is to acquire Silence Therapeutics. The transaction is expected to close in the first quarter of 2027, subject to closing conditions. Financial terms of the deal are not included in the information available.

What it means for your team

  • Divesiran's progress in polycythemia vera will be a development programme to watch; the ASH 2026 oral presentation should bring fuller SANRECO data into the public domain.
  • Market-access and portfolio teams tracking rare haematology should note the pending Merck KGaA acquisition, which is subject to closing conditions and expected in Q1 2027.
  • Until the deal closes, Silence continues to report as an independent company, so any change in programme ownership or sponsor responsibilities would only follow completion.

Company's press release (SEC filing): Silence Therapeutics plc ↗

Article written by VigiEye from the official source (Silence Therapeutics plc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →